Executive interview – VolitionRx

Published on 3 January 2017

VolitionRx is a multi-national company developing simple, easy-to-use, blood-based cancer tests to accurately diagnose a range of cancers.

As cancer screening programmes become more widespread, Volition’s products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to prolong the life of patients and improve their quality of life.

Nu.Q represents a powerful step change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis.
A simple test, just a drop of blood.

Today the company has released some exciting news about its first product – the Nu.Q Colorectal Cancer Screening Triage Test. Watch the interview with CEO Cameron Reynolds.

Share this with friends and colleagues